ScoreWhy is Evoke Pharma, Inc. ?
1
With a growth in Operating Profit of 22.27%, the company declared Very Positive results in Jun 25
- The company has declared positive results for the last 14 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -3.63 MM
- NET PROFIT(HY) Higher at USD -2.88 MM
- ROCE(HY) Highest at -152.92%
2
High Institutional Holdings at 26.46%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 1.5% over the previous quarter.
3
Market Beating performance in long term as well as near term
- Along with generating 148.28% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Evoke Pharma, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Evoke Pharma, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Evoke Pharma, Inc.
159.86%
0.27
226.72%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
69.01%
EBIT Growth (5y)
9.14%
EBIT to Interest (avg)
-8.23
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.29
Sales to Capital Employed (avg)
1.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
26.46%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.75
EV to EBIT
0.63
EV to EBITDA
0.63
EV to Capital Employed
1.83
EV to Sales
-0.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
290.76%
ROE (Latest)
-86.94%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend17What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -3.63 MM
NET PROFIT(HY)
Higher at USD -2.88 MM
ROCE(HY)
Highest at -152.92%
NET SALES(Q)
Highest at USD 3.75 MM
-5What is not working for the Company
OPERATING PROFIT(Q)
Lowest at USD -1.56 MM
PRE-TAX PROFIT(Q)
Lowest at USD -1.57 MM
NET PROFIT(Q)
Lowest at USD -1.57 MM
Here's what is working for Evoke Pharma, Inc.
Operating Cash Flow
Highest at USD -3.63 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 3.75 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Sales
At USD 3.75 MM has Grown at 29.45%
over average net sales of the previous four periods of USD 2.9 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Here's what is not working for Evoke Pharma, Inc.
Operating Profit
Lowest at USD -1.56 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (USD MM)
Pre-Tax Profit
Lowest at USD -1.57 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD -1.57 MM has Fallen at -23.73%
over average net sales of the previous four periods of USD -1.27 MMMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -1.57 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Net Profit
At USD -1.57 MM has Fallen at -23.73%
over average net sales of the previous four periods of USD -1.27 MMMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
